{
    "clinical_study": {
        "@rank": "144506", 
        "arm_group": [
            {
                "arm_group_label": "Intercurrent PSORIAMED", 
                "arm_group_type": "Experimental", 
                "description": "5 minutes twice a day for 12 weeks"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "arm_group_type": "Active Comparator", 
                "description": "V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.\nV1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.\nV2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up  (24 weeks after V1). Clinical scores and photographs."
            }
        ], 
        "brief_summary": {
            "textblock": "Interferential current has shown promising results for treating psoriasis with a good\n      tolerance. Prospective randomized studies versus placebo are required to confirm the\n      interest of such an approach.\n\n      The Main objective is to assess the efficacy of interferential current for treating\n      palmoplantar psoriasis.\n\n      Secondary objectives is to assess the subjective efficacy by the patients, the efficacy on\n      the nails, to study the potential side effects."
        }, 
        "brief_title": "Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis Palm & Soles", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Interferential current has shown promising results for treating psoriasis with a good\n      tolerance. Prospective randomized studies versus placebo are required to confirm the\n      interest of such an approach.\n\n      Main objective To assess the efficacy of interferential current for treating palmoplantar\n      psoriasis.\n\n      Secondary objectives To assess the subjective efficacy by the patients, the efficacy on the\n      nails, to study the potential side effects.\n\n      Patients Patients from 18 to 90 year-old with psoriasis on the hands and/or feet. Length of\n      the study: 12 months Methods Monocentric randomized comparative study versus\n      placebo.Intervention V0 : Selection: Information of the patient, control of inclusion and\n      non inclusion criteria.\n\n      V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be\n      discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and\n      photographs. Explanation of the functioning of the device, then the treatment is followed at\n      home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.\n\n      V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of\n      the follow-up  (24 weeks after V1). Clinical scores and photographs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients from 18 to 90 year-old with psoriasis on the hands and/or feet diagnosed\n             clinically\n\n        Exclusion Criteria:\n\n          -  Pregnant women,\n\n          -  implantable electronic device (such as pace maker), betabloquer.\n\n          -  Concomitant use of a treatment potentially active on psoriasis (steroids, vitamin D\n             analogues, immunosuppressive drug, acitretin, cyclosporine, methotrexate, anti-TNF,\n             anti-IL12/IL23)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01765985", 
            "org_study_id": "11-CRO-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intercurrent PSORIAMED", 
                "description": "V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.\nV1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.\nV2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up  (24 weeks after V1). Clinical scores and photographs.", 
                "intervention_name": "PSORIAMED", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "description": "V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.\nV1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.\nV2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up  (24 weeks after V1). Clinical scores and photographs.", 
                "intervention_name": "PLACEBO", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Salicylates"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "palmoplantar", 
        "lastchanged_date": "January 10, 2013", 
        "location": {
            "contact": {
                "email": "thierry.passeron@unice.fr", 
                "last_name": "PASSERON Thierry, PU-PH", 
                "phone": "+33492039224"
            }, 
            "facility": {
                "address": {
                    "city": "Nice", 
                    "country": "France", 
                    "state": "Alpes-Maritimes", 
                    "zip": "06200"
                }, 
                "name": "ANPRED - H\u00f4pital de l'archet - 151 route de sainte antoine de ginesti\u00e8re"
            }, 
            "investigator": {
                "last_name": "PASSEON Thierry, Pu-PH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current", 
        "overall_contact": {
            "email": "thierry.passeron@unice.fr", 
            "last_name": "PASSERON Thierry, PU-PH", 
            "phone": "+33492039224"
        }, 
        "overall_official": {
            "affiliation": "ANPRED - Service de Dermatologie - H\u00f4pital de l'Archet - 151 Route de saint-antoine de ginesti\u00e8re 06200 Nice", 
            "last_name": "PASSERON Thierry, Pu-Ph", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "IGA (investigator Global assessment) score from 0 (healed) to 4 (worst) at 12 and 24 weeks. The criteria of success will be IGA 0 or 1 at W12.", 
            "measure": "Test IGA", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01765985"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Association Ni\u00e7oise Pour la Recherche En Dermatologie", 
            "investigator_full_name": "Pr PASSERON", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "PASI (Psoriasis Activity Severity Index)", 
                "measure": "PASI (Psoriasis Activity Severity Index)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "PGA (Patient global assessment)", 
                "measure": "PGA (Patient global assessment)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "NAPSI (Nail Activity Psoriasis Severity Index)", 
                "measure": "NAPSI (Nail Activity Psoriasis Severity Index)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Association Ni\u00e7oise Pour la Recherche En Dermatologie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pr PASSERON", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}